Business Context and Reporting Period
This Form 6-K filing by Baird Medical Investment Holdings Ltd covers the month of January 2025, with the report dated January 28, 2025. The filing discloses a change of independent registered public accounting firm effective January 24, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and auditor changes rather than financial performance data.
Material Changes
- Auditor Dismissal: Marcum Asia CPAs LLP was dismissed as the independent registered public accounting firm effective January 24, 2025.
- New Auditor Appointment: Kreit & Chiu CPA LLP (PCAOB ID: 6651) was appointed as the new independent registered public accounting firm for the fiscal year ended December 31, 2024.
- Historical Audit Status: Marcum Asia's reports for fiscal years 2022 and 2023 contained no adverse opinions, disclaimers, or qualifications.
- Disagreements: There were no disagreements with Marcum Asia regarding accounting principles, practices, or audit scope during the relevant periods.
Outlook, Risks, and Contingencies
The filing identifies specific material weaknesses in the Company's internal control over financial reporting, which are considered reportable events:
- Lack of sufficient financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting requirements.
- Lack of a comprehensive accounting policies and procedures manual in accordance with U.S. GAAP and documented controls.
The new auditor, Kreit & Chiu CPA LLP, is aware of these material weaknesses. No consultations regarding accounting matters or reportable events occurred with the new auditor prior to their engagement.
Investor Verification Checklist
- Verify the letter from Marcum Asia CPAs LLP (Exhibit 16.1) confirming their agreement with the Company's statements regarding the dismissal.
- Confirm the PCAOB registration status of Kreit & Chiu CPA LLP (ID: 6651).
- Review the Company's plan to remediate the disclosed material weaknesses in internal controls over financial reporting.
- Monitor future filings for any delays in the issuance of the 2024 annual report due to the auditor transition.